Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. The deal with CVS is the latest this week as Novo Nordisk pushes ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...